Mechanisms of stroke in COVID-19
JD Spence, GR De Freitas, LC Pettigrew, H Ay… - Cerebrovascular …, 2020 - karger.com
In this Commentary, we address mechanisms of stroke in patients with coronavirus disease
2019 (COVID-19) due to infection with the severe acute respiratory syndrome coronavirus-2 …
2019 (COVID-19) due to infection with the severe acute respiratory syndrome coronavirus-2 …
Prosthetic heart valve thrombosis
Although surgery was the mainstay of treatment for valvular heart disease, transcatheter
valve therapies have grown exponentially over the past decade. Two types of artificial heart …
valve therapies have grown exponentially over the past decade. Two types of artificial heart …
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
[HTML][HTML] The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem
IH Jaffer, JI Weitz - Acta biomaterialia, 2019 - Elsevier
Blood-contacting medical devices are an integral part of modern medicine. Such devices
may be used for only a few hours or may be implanted for life. Despite advances in …
may be used for only a few hours or may be implanted for life. Despite advances in …
[HTML][HTML] 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
CE Chiang, K Okumura, S Zhang, TF Chao, CW Siu… - Journal of arrhythmia, 2017 - Elsevier
Atrial fibrillation (AF) is the most common sustained arrhythmia, causing a 2-fold increase in
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European heart rhythm association (EHRA) and …
Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with
valvular heart disease (VHD) is also common. However, management strategies for this …
valvular heart disease (VHD) is also common. However, management strategies for this …
Laboratory monitoring of non–vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review
Importance The non–vitamin K antagonist oral anticoagulants (NOACs) apixaban,
dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without …
dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without …
Antithrombotic agents: new directions in antithrombotic therapy
Recent advances in our understanding of the contribution of thrombin generation to arterial
thrombosis and the role of platelets in venous thrombosis have prompted new treatment …
thrombosis and the role of platelets in venous thrombosis have prompted new treatment …
Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
R De Caterina, G Renda, AP Carnicelli, F Nordio… - Journal of the American …, 2017 - jacc.org
Background: The use of non-vitamin K antagonist oral anticoagulants (NOACs) instead of
vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular …
vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular …
Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure
J Saw, JE Nielsen-Kudsk, M Bergmann… - JACC: Cardiovascular …, 2019 - jacc.org
Objectives: The aim of this study is to review the evidence on the use of antithrombotic
therapy and risk of device-related thrombosis after left atrial appendage closure …
therapy and risk of device-related thrombosis after left atrial appendage closure …